Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.
The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective compared with a placebo in preventing infections caused by a group of bacteria commonly found in the gut.
No safety signals related to the experimental vaccine were identified, J&J said, adding that it was conducting follow-ups for participants currently enrolled in the trial.
The study was testing the safety and efficacy of a single dose of the experimental shot, ExPEC9V, in preventing E.coli disease, including sepsis and blood infections.
Read next
11:56
vaccine
The U.S. FDA has approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE, for adults aged 65 and older and those aged 12–64 with risk factors, marking a major step under tighter regulations.
04:00
U.S. Health Secretary Robert F. Kennedy Jr. has announced that COVID-19 vaccines will no longer be recommended for healthy children and pregnant women — a move that has sparked sharp criticism from public health experts.
10:25
Pakistan kicked off a nationwide anti-polio campaign on Monday, aiming to vaccinate over 45 million children under the age of five as part of efforts to eliminate the crippling disease—one of the last remaining in the world.
17:03
Health News
The U.S. Food and Drug Administration (FDA) has granted approval to Novavax's COVID-19 vaccine, Nuvaxovid, but with specific conditions limiting its use to certain groups.
10:53
Ebola
Uganda has launched a trial vaccination program for the Sudan strain of Ebola as confirmed cases rise to three. With no approved vaccine for this strain, the trial aims to protect communities and strengthen outbreak response, according to the WHO.
What is your opinion on this topic?
Leave the first comment